Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
32results about How to "Inhibit and reduce expression" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA)
ActiveUS7858769B2Down regulating or inhibiting the expression of one or more target nucleicInhibit and reduce expressionSugar derivativesPeptide/protein ingredientsDiseaseBiological body
The present invention concerns methods and nucleic acid based reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, veterinary, agricultural, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to multifunctional short interfering nucleic acid (multifunctional siNA) molecules that modulate the expression of one or more genes in a biologic system, such as a cell, tissue, or organism via RNA interference (RNAi). The bifunctional short interfering nucleic acid (multifunctional siNA) molecules of the invention can target more than one regions of nucleic acid sequence in a single target nucleic acid molecule or can target regions of nucleic acid sequence in differing target nucleic acid molecules. The self multifunctional siNA molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
Owner:SIRNA THERAPEUTICS INC
Compositions and methods for inhibiting expression of KLF-1 and BCL11a genes
ActiveUS20140018410A1Reduce expressionImprove the level ofSugar derivativesVertebrate cellsDouble strandedGene
Owner:ALNYLAM PHARMA INC
Methods for treating and preventing gi syndrome and graft versus host disease
ActiveUS20100239572A1Regulate hepatocyte apoptosisProtected hepatocytesAntipyreticAnalgesicsAutoimmune diseaseT lymphocyte
We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
Owner:THE UNIV OF TEXAS SYST +1
Method of cancer treatment using sirna silencing
ActiveUS20090220582A1Reduction in IDO expressionDecrease in IDO-directed tumoral immunosuppressionOrganic active ingredientsSugar derivativesSirna silencingWilms' tumor
The present invention is a method for the treatment of cancer involving tumor derived immunosuppression in a subject. The method comprises administering to a subject one or more siRNA constructs capable of inhibiting the expression of an immunosuppressive molecule. The invention also provides siRNA constructs and compositions.
Owner:REGEN BIOPHARMA
Rna Interference Mediated Inhibition of Gene Expression Using Multifunctional Short Interfering Nucleic Acid (Multifunctional Sina)
ActiveUS20080039412A1Improve bioavailabilityHigh potencySugar derivativesPeptide/protein ingredientsBiological bodyNucleic acid sequencing
The present invention concerns methods and nucleic acid based reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, veterinary, agricultural, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to multifunctional short interfering nucleic acid (multifunctional siNA) molecules that modulate the expression of one or more genes in a biologic system, such as a cell, tissue, or organism via RNA interference (RNAi). The bifunctional short interfering nucleic acid (multifunctional siNA) molecules of the invention can target more than one regions of nucleic acid sequence in a single target nucleic acid molecule or can target regions of nucleic acid sequence in differing target nucleic acid molecules. The self multifunctional siNA molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
Owner:SIRNA THERAPEUTICS INC
Compositions and methods for inhibiting expression of pro-apoptotic genes
InactiveUS20100222409A1Reducing and preventing symptomInhibit and reduce expressionOrganic active ingredientsSugar derivativesDiseaseKEAP1
The invention relates to one or more inhibitors, in particular siRNA compounds, which down-regulate the expression of a pro-apoptotic gene selected from the group consisting of TP53; HTRA2; KEAP1; SHC1-SHC, ZNHIT1, LGALS3 and HI95. The invention also relates to a pharmaceutical composition comprising the compound, and a pharmaceutically acceptable carrier. The present invention further provides methods of treating a subject afflicted with a disease or a condition associated with those genes, comprising administering to the subject a pharmaceutical composition in a therapeutically effective dose so as to thereby treat the subject.
Owner:QUARK FARMACUITIKALS INC
Method of cancer treatment using siRNA silencing
ActiveUS8389708B2Inhibit and reduce expressionIncreasing T-cell proliferationOrganic active ingredientsSugar derivativesSirna silencingWilms' tumor
Owner:REGEN BIOPHARMA
Composition and methods for inhibiting expression of hypoxia-inducible genes
InactiveUS20060025429A1Reduce and inhibit expressionReducing and inhibiting angiogenesisBiocideGenetic material ingredientsHypoxia responseInducible gene
Methods are provided for interfering with a hypoxia-mediated transcriptional pathway using an agent that binds to a hypoxia response element and inhibits transcription of a hypoxia inducible gene associated therewith. Also provided are methods of treating a patient with a solid tumors, and compositions useful for treating a patient having solid tumors, including, for example, by administering an agent that binds to a hypoxia response element in a cell. Agents for the methods of the invention are provided including compositions comprising a pyrrole imidazole polyamide or a pharmaceutically acceptable salt or complex thereof.
Owner:CALIFORNIA INST OF TECH
Method for evaluating cell aging by expression level of cofilin
ActiveUS8574852B2Improve expression levelImprove cellular senescenceMicrobiological testing/measurementArtificial cell constructsTissue sampleBiology
The present invention discloses a concept that the expression level of cofilin may reflect the senescent condition of a cell or tissue. According to the findings in present invention, a method for determining the cellular senescent condition in a cell or tissue sample by evaluating the expression level of cofilin is provided. The detection of the expression level of cofilin is also used to screen an effective compound or composition for regulating the senescent condition in target cells.
Owner:NATIONAL YANG MING UNIVERSITY
Compositions and methods for reducing or protecting against delayed graft function (DGF)
InactiveUS8785408B2Reducing and preventing symptomInhibit and reduce expressionSugar derivativesGenetic material ingredientsDiseaseApoptotic gene
The invention relates to one or more inhibitors, in particular siRNA compounds, which down-regulate the expression of a pro-apoptotic gene selected from the group consisting of TP53; HTRA2; KEAP1; SHC1-SHC, ZNHIT1, LGALS3 and HI95. The invention also relates to a pharmaceutical composition comprising the compound, and a pharmaceutically acceptable carrier. The present invention further provides methods of treating a subject afflicted with a disease or a condition associated with those genes, comprising administering to the subject a pharmaceutical composition in a therapeutically effective dose so as to thereby treat the subject.
Owner:QUARK FARMACUITIKALS INC
Methods for monitoring polymorphonuclear myeloid derived suppressor cells, and compositions and methods of treatment of cancer
InactiveUS20180059115A1Reducing and inhibiting stress responseInhibit and reduce expressionMicrobiological testing/measurementBiological material analysisLymphatic SpreadMyeloid-derived Suppressor Cell
A method of obtaining a population of cells enriched in human polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs) comprises isolating from a cell suspension those cells which express LOX-1 to provide a population of cells enriched with PMN-MDSCs. A method of monitoring the population of LOX-1+ cells in a cell-containing biological sample is useful for determining the efficacy of treatment or the metastasis or increasing progression of cancer. Other cell isolation and diagnostic methods are also described. A composition for use in diagnosing and treating cancer related to PMN-MDSC is provided that contains antagonists and / or inhibitors of genes related to the ER stress response.
Owner:THE WISTAR INST OF ANATOMY & BIOLOGY
Rny-derived small rnas as biomarkers for atherosclerosis-related disorders
ActiveUS20160237500A1Reduce riskNegative correlationHydrolasesPeptide/protein ingredientsDrugRelated disorder
The present invention concerns an in vitro method of diagnosis or prognosis of an atherosclerosis-related disorder by detecting a small Y RNA (s-RNY), as well as the use of an inhibitor of s-RNY as a medicament against atherosclerosis-related disorders. The invention also concerns a method for screening for a compound suitable for the treatment of an atherosclerosis-related disorder.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
Compositions and Methods for Increasing Pest Resistance in Plants
InactiveUS20150211019A1Improve pest resistanceInhibit and reduce expressionClimate change adaptationTransferasesTransgenePlant composition
Compositions and methods of reducing expression of a flavonoid glucosyltransferase plants, and transgenic and hybrid plants with increased pest resistance are disclosed. The plants can express a polynucleotide that alters, reduces, or silences expression of a flavonoid glucosyltransferase. The flavonoid glucosyltransferase can be Glyma07g14530, or a variant, homolog, or ortholog thereof. Compositions and methods for placing a gene of interest under an expression control sequence of Glyma07g14530, or a fragment thereof, and transgenic and hybrid plants containing one or more herbivory-inducible genes are disclosed. The plants can include a polynucleotide having 50, 100, 150, 250, 500, 750, 1,000, 1,250, 1,500, or 2,000 or more nucleotides of an expression control sequence of Glyma07g14530 operable linked to a nucleic acid encoding a gene of interest. The plants can include one or more transgenes or QTLs that increases insect resistance, for example a Bt transgene, or a Pb, QTL-H, or QTL-G.
Owner:UNIV OF GEORGIA RES FOUND INC
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
ActiveUS20200354720A1Inhibit and reduce expressionReduce protein expressionOrganic active ingredientsNervous disorderMedical disorderExon
The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
Owner:ROCHE INNOVATION CENT COPENHAGEN
Anti-Axl antagonistic antibodies
ActiveUS11198734B2Good effectImprove expression levelImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntiendomysial antibodiesAnti antibody
Owner:BERGEN TEKNOLOGIOVERFORING AS +1
Methods for treating GI syndrome and graft versus host disease
ActiveUS8562993B2Regulate hepatocyte apoptosisProtected hepatocytesAntipyreticAnalgesicsAutoimmune diseaseT lymphocyte
We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1
Medicament for treatment of liver cancer
InactiveUS20200000787A1Good curative effectAvoid it happening againPeptide/protein ingredientsAntineoplastic agentsPharmaceutical drugOncology
The invention provides a pharmaceutical composition comprising Sorafenib in combination with an inhibitor of a specific kinase inhibitor as a medicament for the treatment or prevention of liver cancer.
Owner:GESELLSCHAFT FUR BIOTECHNOLOGISCHE FORSCHUNG MBH GBF
Compositions and methods for self-regulated inducible gene expression
ActiveUS10392622B2Reduces any “leakiness”Stable expressionVectorsVector-based foreign material introductionDiseaseAptamer
A self-regulating gene expression construct comprises a single promoter in operative association with a repressor sequence (e.g., bacterial repressor lacI or gaiR), operator sequence(s) responsive to the expressed repressor protein, and a transgene. A dual-regulating construct comprises a single promoter controlling expression of a bacterial repressor sequence and a transgene, and which, in the presence of a first inducer molecule, transcribes the transgene and repressor; and a ribozyme in association with an aptamer sequence, the aptamer sequence capable of interacting with a second inducer molecule to terminate mRNA degradation by the ribozyme. Also provided are recombinant vectors or viruses containing the self-regulating or dual self-regulating constructs and cells containing the vectors. Such compositions are useful in methods of treating a diseases using gene therapy.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Compositions and methods for self-regulated inducible gene expression
ActiveUS20170218379A1Inhibit and reduce expressionTight regulationFermentationVector-based foreign material introductionDiseaseAptamer
A self-regulating gene expression construct comprises a single promoter in operative association with a repressor sequence (e.g., bacterial repressor lacI or gaiR), operator sequence(s) responsive to the expressed repressor protein, and a transgene. A dual-regulating construct comprises a single promoter controlling expression of a bacterial repressor sequence and a transgene, and which, in the presence of a first inducer molecule, transcribes the transgene and repressor; and a ribozyme in association with an aptamer sequence, the aptamer sequence capable of interacting with a second inducer molecule to terminate mRNA degradation by the ribozyme. Also provided are recombinant vectors or viruses containing the self-regulating or dual self-regulating constructs and cells containing the vectors. Such compositions are useful in methods of treating a diseases using gene therapy.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Compositions and methods for inhibiting expression of the LECT2 gene
ActiveUS10077444B2Reducing size and number and extentAvoid depositionOrganic active ingredientsSugar derivativesLECT2 geneDouble stranded
Owner:ALNYLAM PHARMA INC
Method for evaluating cell aging by expression level of cofilin
ActiveUS20130004962A1Arrest and slow down cell aging in cellInhibit and reduce expressionMicrobiological testing/measurementVertebrate cellsTissue sampleBiology
The present invention discloses a concept that the expression level of cofilin may reflect the senescent condition of a cell or tissue. According to the findings in present invention, a method for determining the cellular senescent condition in a cell or tissue sample by evaluating the expression level of cofilin is provided. The detection of the expression level of cofilin is also used to screen an effective compound or composition for regulating the senescent condition in target cells.
Owner:NATIONAL YANG MING UNIVERSITY
Coronavirus irna compositions and methods of use thereof
PendingUS20220127615A1Inhibit and reduce expressionInhibit expressionAgainst vector-borne diseasesDNA/RNA fragmentationDiseaseVirology
The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the coronavirus genome. The invention also relates to methods of using such RNAi agents to inhibit expression of a coronavirus genome and to methods of treating or preventing a coronavirus-associated disease in a subject.
Owner:VIR BIOTECH INC +1
RNY-derived small RNAs as biomarkers for atherosclerosis-related disorders
ActiveUS10208351B2Reduce riskNegative correlationPeptide/protein ingredientsHydrolasesDiseaseAtheroma
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
Prophylaxis and Treatment of Enteropathogenic Bacterial Infection
InactiveUS20140057993A1Reducing and suppressing inflammationInhibit and reduce expressionBiocideOrganic chemistryAntidiarrheal AgentΒ1 integrins
In accordance with the present invention, methods are provided for the prevention and / or treatment of enteropathogenic bacterial infection in the gastrointestinal tract of a subject, and the diarrhea associated with the infection, by administration to the subject of a low molecular weight polyethylene glycol, as well concurrent administration with other antibiotic and antidiarrheal agents. Methods for reduction or suppression of inflammation, and inhibition of β1-integrin expression in the gastrointestinal mucosa are also provided. Also described is a kit suitable for use with the methods disclosed.
Owner:NORTHSHORE UNIV HEALTHSYST
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
Owner:ALNYLAM PHARMA INC
Compositions and methods for treating metabolic disorders
PendingUS20210346328A1Rescued structureModify joint destructionSkeletal disorderKetone active ingredientsSubchondral boneCartilage degeneration
Provided herein are methods of treating, delaying progression of, or reducing the severity of metabolic disorders characterized with increased COX-2 expression and / or PGE2 expression and / or EP4 expression in bone related cells through administration of an agent configured to inhibit and / or diminish COX-2 expression, and / or PGE2 expression, and / or EP4 expression in bone related cells. In some embodiments, such administration results in one or more of the following: inhibited or reduced COX-2 expression; inhibited or reduced PGE2 expression; inhibited or reduced EP4 expression; inhibited or reduced aberrant subchondral bone remodeling and / or innervation; inhibited or reduced cartilage degeneration; and inhibited or reduced joint destruction.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Methods for Monitoring Polymorphonuclear Myeloid Derived Suppressor Cells and Compositions and Methods of Treatment of Cancer
PendingUS20210148916A1Reduces and inhibits ER stressInhibit and reduce expressionMicrobiological testing/measurementBiological material analysisOncologyCell separation
A method of obtaining a population of cells enriched in human polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs) comprises isolating from a cell suspension those cells which express LOX-1 to provide a population of cells enriched with PMN-MDSCs. A method of monitoring the population of LOX-1+ cells in a cell-containing biological sample is useful for determining the efficacy of treatment or the metastasis or increasing progression of cancer. Other cell isolation and diagnostic methods are also described. A composition for use in diagnosing and treating cancer related to PMN-MDSC is provided that contains antagonists and / or inhibitors of genes related to the ER stress response.
Owner:THE WISTAR INST OF ANATOMY & BIOLOGY
Antisense compositions targeted to beta1-adrenoceptor-specific mRNA and methods of use
InactiveUS20030191080A1Inhibit and reduce expressionReduce inhibitionOrganic active ingredientsFungiNucleotideTherapeutic effect
Disclosed are antisense oligonucleotide, polynucleotide, and peptide nucleic acid compounds that specifically bind to mammalian mRNA encoding a beta1-adrenoceptor polypeptide and that are useful in the control and / or treatment of cardiac dysfunction, hypertension, hypertrophy, myocardial ischemia, and other cardiovascular diseases in an affected mammal, and preferably, in a human subject. The antisense compounds disclosed herein, and pharmaceutical formulations thereof, provide sustained control of beta1-adrenoceptor expression over prolonged periods, and achieve therapeutic effects from as little as a single dose. Administration of these antisense compositions to approved animal models resulted in a decrease in blood pressure, but no significant change in heart rate. Use of such antisense compositions in the reduction of beta1-adrenoceptor polypeptides in a host cell expressing beta1-adrenoceptor-specific mRNA, and in the preparation of medicaments for treating human and animal diseases, and in particular, hypertension and other cardiac dysfunction is also disclosed.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Application of yew polysaccharide in preparing medicament for myocardial ischemia-reperfusion injury
InactiveCN101375857BImprove complianceInhibit apoptosisOrganic active ingredientsCardiovascular disorderSerum igeApoptosis
Owner:台州市中心医院 +1
Nrf-2 deficient cells and uses thereof
PendingUS20220016169A1Reduce tumor volumeReduce levelImmunoglobulin superfamilyGenetically modified cellsSolid CarcinomaImmunotherapy
The present disclosure relates to T cell anticancer immunotherapy based on modulation of Nrf2 expression, that is, to an Nrf2-targeting immune cell, e.g., T cell, anticancer therapy. The present disclosure allows deep interference with the Nrf2 expression in T cells, thereby solving the problem of immune tolerance shown by cancer cells to T cells; in other words, the effect of anticancer immunotherapy can be improved by targeting Nrf2. The present disclosure can provide an Nrf2-targeting new T cell anticancer immunotherapy and a T cell for the second-generation anticancer immunotherapy. This technology is applicable to the preparation of CAR-T, engineered T, and TIL T cells, and to the treatment of various solid carcinomas, including lymphoma. It can be said to be a new anticancer therapy that improves the therapeutic efficacy effectively.
Owner:NEOIMMUNETECH INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com